A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE

OBJECTIVES: SLE is a severe autoimmune disease characterized by autoreactive B cells and IC formation, which causes systemic inflammation. B cell–targeted therapy could be a promising treatment strategy in SLE patients; nevertheless, randomized clinical trials have not always been successful. Howeve...

Descripción completa

Detalles Bibliográficos
Autores principales: van Dam, Laura S, Osmani, Zgjim, Kamerling, Sylvia W A, Kraaij, Tineke, Bakker, Jaap A  , Scherer, Hans U, Rabelink, Ton J, Voll, Reinhard E, Alexander, Tobias, Isenberg, David A, van Kooten, Cees, Teng, Y K Onno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516125/
https://www.ncbi.nlm.nih.gov/pubmed/31951278
http://dx.doi.org/10.1093/rheumatology/kez623

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516125/
https://www.ncbi.nlm.nih.gov/pubmed/31951278
http://dx.doi.org/10.1093/rheumatology/kez623

Ejemplares similares